A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbladder carcinoma (IMMUCHEC) [Eine randomisierte Phase-II-Studie mit Durvalumab und Tremelimumab in Kombination mit Gemcitabin oder Gemcitabin und Cisplatin verglichen mit Gemcitabin und Cisplatin bei nicht-vorbehandelten Patienten mit Gallengangs- und Gallenblasenkrebs]

Trial Profile

A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbladder carcinoma (IMMUCHEC) [Eine randomisierte Phase-II-Studie mit Durvalumab und Tremelimumab in Kombination mit Gemcitabin oder Gemcitabin und Cisplatin verglichen mit Gemcitabin und Cisplatin bei nicht-vorbehandelten Patienten mit Gallengangs- und Gallenblasenkrebs]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Acronyms IMMUCHEC
  • Most Recent Events

    • 19 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 16 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top